Key facts
- Notable investors include Hefei Industry Investment Group, Hangzhou Hi-Tech Financial Investment Group, Chenghe Ventures, Hangzhou Tianhe Hi-Tech, Shulan Junjie Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Difurunsi
- ·The full record, as it builds
Funding rounds
No funding rounds for Difurunsi are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Difurunsi
Developer of recombinant virus technology application platform and IVD products intended for genetic engineering on various viral vectors. The company offers innovation in genetic engineering vaccines for major infectious diseases, oncolytic viruses, viral vectors, mRNA presentation, virus tracing, and visual nucleic acid detection, and has constructed the world's first recombinant new disease virus vector COVID-19 vaccine candidate and has developed the world's first whole virus inactivated vaccine for avian influenza that distinguishes between infected and immune animals.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2017
- Website
- diff-biotech.com/
- Ownership
- Privately Held (backing)
Difurunsi doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Difurunsi shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Difurunsi in its N-PORT filings yet. We sweep new filings monthly.